FDA unveils risk-management program for ESAs

Traynor, Kate
April 2010
American Journal of Health-System Pharmacy;4/1/2010, Vol. 67 Issue 7, p508
Academic Journal
The article reports on the risk management program for erythropoiesis-stimulating agents (ESAs) disclosed by the U.S. Food and Drug Administration (FDA) in February 2010. It says that the risk evaluation and mitigation strategy (REMS) ensures the compliance of prescribers at hospitals in the Assisting Providers and cancer Patients with Risk Information for the Safe use of ESAs (APPRISE) program. It says that ESAs will not be available to those prescribers who are not registered in APPRISE.


Related Articles

  • Risks and Realities of REMS. Wechsler, Jill // Pharmaceutical Technology;Apr2010, Vol. 34 Issue 4, p28 

    The article discusses the impact of Risk Evaluation and Mitigation Strategy (REMS) of the U.S. Food and Drug Administration (FDA) on drug development and regulatory strategies. It indicates that REMS has encountered issues about high-risk drugs and drug classes used in cancer treatment. It...

  • Erythropoiesis-stimulating agents.  // WHO Drug Information;2008, Vol. 22 Issue 1, p15 

    The article alerts the public of the adverse effects of using erythropoiesis-stimulating agents (ESA) in cancer patients in the U.S. The Food and Drug Administration (FDA) strengthened the warning sections for products containing ESA due to the results of a clinical study which reveals decreased...

  • ODAC calls for more restrictions on ESAs. Shafer, Emily // Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p1 

    The article reports that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. has voted for the marketing of erythropoiesis-stimulating agents as treatment for chemotherapy-induced anemia. ODAC has also voted against restricting the use of the drugs in small cell lung cancer treatment. ODAC...

  • Changes for ESAs. Spalding, B J // Nature Biotechnology;May2008, Vol. 26 Issue 5, p483 

    This article reports that the Oncology Drug Advisory Committee of the U.S. Food and Drug Administration made new recommendations regarding three erythropoiesis-stimulating agents (ESAs) in March 2008. The ESAs discussed were Epogen, Aranesp, and Procrit and it was decided that ESAs will not be...

  • Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes. Stroupe, Kevin; Tarlov, Elizabeth; Weichle, Thomas; Zhang, Qiuying; Michaelis, Laura; Ozer, Howard; Durazo-Arvizu, Ramon; Hynes, Denise // Supportive Care in Cancer;Dec2014, Vol. 22 Issue 12, p3153 

    Purpose: Use of erythropoiesis-stimulating agents (ESAs) in US cancer care declined amidst post-marketing evidence of adverse effects and the Food and Drug Administration's (FDA) addition of a 'black-box' warning to product labeling in March 2007. Because reduced ESA use may have led to more...

  • New Limits Advised for Anemia Drugs. Mitka, Mike // JAMA: Journal of the American Medical Association;6/13/2007, Vol. 297 Issue 22, p2464 

    This article explains that members of the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration voted to place restrictions on the use of genetically engineered erythropoiesis-stimulating agents (ESAs) that are used to treat anemia associated with certain types of cancer....

  • REMS for ESAs: The FDA mandated program is under scrutiny.  // Hem/Onc Today;7/10/2010, Vol. 10 Issue 13, p1 

    The article addresses the Risk Evaluation and Mitigation Strategy (REM) approved by the U.S. Food and Drug Administration (FDA) for erythropoiesis-stimulating agents (ESA).

  • ESAs: the need for optimal targets, dosing and monitoring.  // Reactions Weekly;1/30/2010, Issue 1286, p6 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to create a public advisory committee in 2010 to reevaluate the use erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease in relation to data from three large clinical trials which claim...

  • Supplier Control: Growing Regulatory Concern for Outsourcing. Miller, Marc // Medical Product Outsourcing;2009, Vol. 7 Issue 6, p22 

    The article discusses the significance of manufacturers to take a careful review of their supplier control practices in the U.S. It explores the discussion on risk illustration and valuable mitigations for effective supplier control made by Kim Trautman, medical device quality systems/GMP expert...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics